About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

AbbVie’s (ABBV) mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company lost 12.6% on Monday in response to the disappointing news. However, Bristol Myers’ (BMY) stock was up 10.5% following ABBV’s news.The studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score upon treatment with the candidate compared with the placebo group at week 6 ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Malu Dreyer, Minister President of ... [+] Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie. Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesAbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clin ...

I last wrote on AbbVie Inc. (NYSE: ABBV ) back in September 2024 and on Pfizer Inc. (NYSE: PFE ) back in August 2024. These articles are titled “AbbVie: Dividend Discount As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite t ...

AbbVie (NYSE: ABBV ) shares are plummeting as the company's schizophrenia treatment drug reportedly failed to meet its primary endpoint in a late-state study. While certainly a blow, the resulting drop of nearly 10% as I write this appears to be significantlyTo follow me click the "Follow" button! (Easy right?) Hi there, thanks for coming to my profile page! My name is Kumquat Research (but you can call me Jeremy) and I've been writing for Seeking Alpha on and off for going on ten years now, beginning with ...

A splashy recent acquisition by the company might not be panning out.Disappointing news from the laboratory weighed on AbbVie (ABBV -12.53%) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did not do well in recent testing. On the company's latest readout, investors were aggressively trading out of the shares, leaving them with a 12% decline in late-afternoon trading.Schizophrenia drug didn't do well in the labJust before the market op ...

On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.PANSS is a scale used for measuring the symptom severity of schizophrenia.Also Read: Bristol-Myer ...

Key TakeawaysShares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.Abbvie said the trials did not show a statistically significant improvement in symptoms compared with the placebo group at week 6.Meanwhile, shares of Bristol Myers Squibb, makers of recently approved schizophrenia treatment Cobenfy, soared 12%. Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pai ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.AbbVie Inc. (NYSE: ABBV ) announced today that emraclidine failed in bot ...

About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...